

## **Non Renounceable pro rata offer – Completion of despatch**

**31 July 2020**, Melbourne: Rhythm Biosciences Limited (ASX: RHY) (Rhythm or the Company) advises that the Offer Document and Application Form for the non-renounceable pro rata offer (Entitlement Offer) announced to ASX on 23 July 2020 has been despatched.

Notifications have also been sent to ineligible foreign shareholders pursuant to ASX Listing Rule 7.7.1(b).

For all enquiries concerning the Offer Document, please contact the Company on +61 3 9614 0600.

Released with the authority of the Board.

For further information, please contact:

Glenn Gilbert  
Chief Executive Officer

### **About Rhythm Biosciences**

ASX-listed Rhythm Biosciences is endeavoring to develop and commercialise a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT<sup>®</sup>, is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT<sup>®</sup> also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT<sup>®</sup> is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure.

ColoSTAT<sup>®</sup> has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer. Globally, over 850,000 people die from colorectal cancer each year.

---

**Rhythm Biosciences**

ACN: 619 459 335  
ASX: RHY

**Issued Capital**

115,862,000 Shares  
3,000,000 Options

**Australian Registered Office**

Level 2, 480 Collins Street  
Melbourne VIC 3000  
[www.rhythmbio.com](http://www.rhythmbio.com)

**Directors**

Otto Buttula – Chairman of the Board  
Trevor John Lockett – Executive Director  
Louis James Panaccio – Non-Executive Director  
David John White – Non-Executive Director  
Eduardo Vom – Non-Executive Director